Best CDMOs in Japan — Ranked by Signal Score · 2026

Last updated: 2026-08-18 · updated as new inspection, certificate, and trial data enters the platform

USA Europe Asia UK India Switzerland Germany South Korea Japan China

CDMOs in region

Fully scored

With FDA records

FDA inspections

EMA/MHRA GMP certs

CDMO Signal tracks 13 biopharma CDMOs with confirmed Japan manufacturing facilities, of which 7 are fully scored across the four-pillar composite Signal Score. Across all modalities, Ajinomoto Bio-Pharma Services, Minaris Advanced Therapies, and AGC Biologics lead the Japan ranking by composite score. Signal Score integrates FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor footprint, and monitored capacity signals. For modality-specific rankings within Japan — AAV, cell therapy, biologics, and 10 other tracked modalities — see the modality-region breakdown below. Full methodology at cdmosignal.com/methodology.

Japan-based CDMOs ranked by CDMO Signal's composite Signal Score, filtered to manufacturers with confirmed Japanese facilities. Japan's PMDA is regarded as one of the most rigorous regulators globally, with GMP requirements broadly aligned with FDA and EMA. Japanese CDMOs are strong across biologics, small molecules, and increasingly cell therapy (Japan's regenerative medicine regulatory framework is one of the most-developed for advanced therapies). This ranking includes any CDMO with a Japanese manufacturing site.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	AJ Ajinomoto Bio-Pharma Services San Diego, CA · Osaka, JP	85.6	100.0	0 insp · 1 GMP	—	0 programs
2	MN Minaris Advanced Therapies Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP	83.5	100.0	1 insp · 6 GMP	Limited	0 programs
3	AG AGC Biologics Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP	80.6	99.9	2 insp · 23 GMP	Available	2 programs
4	HG Hitachi Global Life Solutions (CGT) Yokohama, Japan	63.0	—	—	—	0 programs
5	SM Sumitomo Chemical Advanced Medical Tokyo, JP	63.0	—	—	—	0 programs
6	Minaris (WuXi Advanced Therapies) Philadelphia, PA / Yokohama, Japan	60.5	—	—	—	0 programs
7	TR Takara Bio Kusatsu, Shiga Prefecture, Japan	59.5	—	—	—	8 programs
—	ARCALIS, Inc. Minamisoma, Fukushima, Japan	Profiled	—	—	—	0 programs
—	Meiji Seika Pharmatech Co., Ltd. Odawara, Japan	Profiled	—	—	—	0 programs
—	Otsuka Pharmaceutical Factory (OPF) Naruto, Japan	Profiled	—	—	—	0 programs
—	Daiichi Sankyo (Manufacturing / Daiichi Sankyo Propharma) Tokyo, Japan	Profiled	—	—	—	0 programs
—	PeptiStar Inc. Yamagata, Japan	Profiled	—	—	—	0 programs
—	GeneDesign, Inc. (now part of Ajinomoto Bio-Pharma Services) Osaka, Japan	Profiled	—	—	—	0 programs

How we score CDMOs →

How does Japan's regenerative medicine regulatory framework affect cell and gene therapy CDMOs?

Japan operates one of the most developed advanced-therapy regulatory frameworks globally, distinguishing between three product classes with tailored requirements: regenerative medical products, cellular/tissue-based products, and gene therapy products. The framework's conditional and time-limited early approval pathway (introduced 2014, revised 2024) has accelerated advanced-therapy commercialization in Japan compared to most other markets. For CDMOs, this means Japanese advanced-therapy manufacturers have accumulated real experience with regulatory-supported early commercial supply — a signal that materially differs from the more restrictive US and EU pathways. Cross-reference with cell therapy, AAV, and cell & gene therapy umbrella pages for Japanese CDMO capability at the modality level.

PMDA regulatory posture — how does it compare to FDA and EMA?

PMDA GMP is generally regarded as tier-equivalent to FDA and EMA — inspections are rigorous, the framework is well-documented, and PMDA participates in the PIC/S mutual-recognition framework alongside EMA and other major regulators. For Japanese-manufactured product supplying US or EU markets, the qualifying signal is FDA or EMA inspection posture on the specific facility (not just PMDA certification), because FDA and EMA conduct their own facility inspections regardless of PMDA status. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly. Japanese CDMOs supplying global markets typically hold cross-jurisdictional certification.

Which Japanese CDMOs supply US and European markets?

The Japanese CDMOs with US and EU inspection posture typically operate global site networks or maintain FDA-inspected export facilities. Cross-check with the US region ranking and Europe region ranking to identify Japanese CDMOs appearing across regions — these have demonstrated multi-jurisdictional inspection posture. Individual profile pages surface facility-level detail on which specific Japanese sites carry which regulatory certifications.

Browse by modality within Japan

Modality-specific rankings for Japan-manufactured programs. Each page filters the modality's global ranking to CDMOs with confirmed Japan facilities.

AAV / Gene Therapy (2) CAR-T (5) Lentiviral Vector (2) Cell Therapy (5) mRNA / LNP (1) Plasmid DNA (1) Biologics / mAb (2) Oligonucleotide / ASO (4) Recombinant Proteins (1) ADC (Antibody-Drug Conjugate) (3) Gene Therapy (3) Cell & Gene Therapy (7) Viral Vector (3)

Other regions

CDMOs in United States CDMOs in Europe CDMOs in Asia CDMOs in United Kingdom CDMOs in India CDMOs in Switzerland CDMOs in Germany CDMOs in South Korea CDMOs in China